Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Goldstone

Showing results (221-230 of 311) with videos related to

Pageof 32
Sort By:
British Journal of Haematology|October 16, 1999
A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working PartiesK Wheatley, A K Burnett, A H Goldstone, et al.
British Journal of Haematology|June 1, 1992
Mini-BEAM followed by BEAM and ABMT for very poor risk Hodgkin's diseaseR Chopra, D C Linch, A K McMillan, et al.
Bone Marrow Transplantation|June 6, 2017
The evolving role of chemotherapy and hematopoietic cell transplants in Ph-positive acute lymphoblastic leukemia in adultsM R Litzow, A K Fielding, S M Luger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 1998
Back-up bone marrow is frequently ineffective in patients with poor peripheral-blood stem-cell mobilizationM J Watts, A M Sullivan, D Leverett, et al.
British Journal of Haematology|July 27, 2005
Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimensKirit M Ardeshna, Nicholaos Kakouros, Wendi Qian, et al.
British Journal of Haematology|January 1, 1993
Treatment of aplastic anaemia (AA) with antilymphocyte globulin (ALG) and methylprednisolone (MPred) with or without androgens: a randomized trial from the EBMT SAA working partyA Bacigalupo, M Chaple, J Hows, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 27, 2007
High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphomaAdrian J C Bloor, Kirsty Thomson, Noha Chowdhry, et al.
British Journal of Haematology|March 1, 1993
Acute hepatitis C infection in patients undergoing therapy for haematological malignancies: a clinical and virological studyN S Brink, R Chopra, C J Perrons, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2010
Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trialAlan K Burnett, Robert K Hills, Donald Milligan, et al.
British Journal of Haematology|January 21, 2014
Autologous stem cell transplantation for follicular lymphoma is of most benefit early in the disease course and can result in durable remissions, irrespective of prior rituximab exposureJaimal Kothari, Karl S Peggs, Antonia Bird, et al.
Pageof 32

Showing results (221-230 of 311) with videos related to

Sort By:
Pageof 32
British Journal of Haematology|October 16, 1999
A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working PartiesK Wheatley, A K Burnett, A H Goldstone, et al.
British Journal of Haematology|June 1, 1992
Mini-BEAM followed by BEAM and ABMT for very poor risk Hodgkin's diseaseR Chopra, D C Linch, A K McMillan, et al.
Bone Marrow Transplantation|June 6, 2017
The evolving role of chemotherapy and hematopoietic cell transplants in Ph-positive acute lymphoblastic leukemia in adultsM R Litzow, A K Fielding, S M Luger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 1998
Back-up bone marrow is frequently ineffective in patients with poor peripheral-blood stem-cell mobilizationM J Watts, A M Sullivan, D Leverett, et al.
British Journal of Haematology|July 27, 2005
Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimensKirit M Ardeshna, Nicholaos Kakouros, Wendi Qian, et al.
British Journal of Haematology|January 1, 1993
Treatment of aplastic anaemia (AA) with antilymphocyte globulin (ALG) and methylprednisolone (MPred) with or without androgens: a randomized trial from the EBMT SAA working partyA Bacigalupo, M Chaple, J Hows, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 27, 2007
High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphomaAdrian J C Bloor, Kirsty Thomson, Noha Chowdhry, et al.
British Journal of Haematology|March 1, 1993
Acute hepatitis C infection in patients undergoing therapy for haematological malignancies: a clinical and virological studyN S Brink, R Chopra, C J Perrons, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2010
Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trialAlan K Burnett, Robert K Hills, Donald Milligan, et al.
British Journal of Haematology|January 21, 2014
Autologous stem cell transplantation for follicular lymphoma is of most benefit early in the disease course and can result in durable remissions, irrespective of prior rituximab exposureJaimal Kothari, Karl S Peggs, Antonia Bird, et al.
Pageof 32